Foundation Medicine Inc. is a cancer diagnostics company that is driven towards providing comprehensive genomic care to patients diagnosed with cancer. The company is headquartered in Cambridge, Massachusetts with a team of medical experts heading the company. Foundation Medicine also collaborates with commercial and academic organizations to develop deeper understanding of cancer genomics.

Today, Foundation Medicine Inc. announced filing a proposed initial public offering (IPO) with the Securities and Exchange Commission. The filing of a Registration Statement on Form S-1 stated all company shares are to be sold in the proposed IPO. The initial public offering will be listed on The NASDAQ Stock Market under the trading symbol FMI, which is still subject to regulatory approval.

The bookrunning managers for the IPO are Goldman Sachs & Co. and JPMorgan Securities LLC. A statement of registration was already filed with the SEC but has not yet been approved. The trading of the company shares of common stock will only take effect after regulatory clearance is issued.